GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

Active filtersClassification:Core

Showing 229-240 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2022CrossrefDirectly related27 citations

Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes

Christophe E. M. De Block; Eveline Dirinck; Ann Verhaegen; Luc F. Van Gaal

May 1, 2022Diabetes, Obesity and Metabolism

2022Semantic ScholarDirectly related126 citations

The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome

Krzysztof Bednarz; Karolina Kowalczyk; Marlena Cwynar; Dominika Czapla; Wiktor Czarkowski; Dominika Kmita; Artur Nowak; P. Madej

Apr 1, 2022International Journal of Molecular Sciences6 influential

2022CrossrefDirectly related145 citations

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment

Stefan Trapp; Daniel I. Brierley

Feb 1, 2022British Journal of Pharmacology

2021OpenAlexDirectly related456 citations

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Xin Zhao; Minghe Wang; Zhitong Wen; Zhihong Lu; Lijuan Cui; Chao Fu; Huan Xue; Yunfeng Liu; Yi Zhang

Aug 23, 2021Frontiers in Endocrinology

2021OpenAlexDirectly related2,036 citations

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frías; Melanie J. Davies; Julio Rosenstock; Federico C. Pérez Manghi; Laura Fernández Landó; Brandon K. Bergman; Bing Liu; Xuewei Cui; Katelyn Brown

Jun 25, 2021New England Journal of Medicine

2021CrossrefDirectly related0 citations

Once weekly semaglutide for treatment of obesity

Nasser Mikhail

Apr 23, 2021Journal of Clinical and Laboratory Research

2020OpenAlexDirectly related2,009 citations

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome; Kristine Buchholtz; Kenneth Cusi; Martin Linder; Takeshi Okanoue; Vlad Ratziu; Arun J. Sanyal; Anne‐Sophie Sejling; Stephen A. Harrison

Nov 13, 2020New England Journal of Medicine

2020OpenAlexDirectly related1,622 citations

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

Michael A. Nauck; Daniel R. Quast; Jakob Wefers; Juris J. Meier

Oct 14, 2020Molecular Metabolism

2019OpenAlexDirectly related1,837 citations

Glucagon-like peptide 1 (GLP-1)

Timo D. Müller; Brian Finan; Stephen R. Bloom; David A. D’Alessio; Daniel J. Drucker; Peter R. Flatt; Andreas Fritsche; Fiona M. Gribble; Harvey J. Grill; Joel F. Habener; Jens J. Holst; Wolfgang Langhans; Juris J. Meier; Michael A. Nauck; Diego Pérez–Tilve; Alessandro Pocai; Frank Reimann; Darleen A. Sandoval; Thue W. Schwartz; Randy J. Seeley; Kerstin Stemmer; Mads Tang‐Christensen; Stephen C. Woods; Richard D. DiMarchi; M. Tschöp

Sep 30, 2019Molecular Metabolism

2019OpenAlexDirectly related967 citations

The Discovery and Development of Liraglutide and Semaglutide

Lotte Bjerre Knudsen; Jesper Lau

Apr 12, 2019Frontiers in Endocrinology

2018OpenAlexDirectly related866 citations

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Tamer Coşkun; Kyle W. Sloop; Corina Loghin; Jorge Alsina‐Fernandez; Shweta Urva; Krister Bokvist; Xuewei Cui; Daniel A. Briere; Over Cabrera; William C. Roell; Uma Kuchibhotla; Julie S. Moyers; Charles Benson; Ruth E. Gimeno; David A. D’Alessio; Axel Haupt

Oct 3, 2018Molecular Metabolism

2018CrossrefDirectly related0 citations

Short Duration of Diabetes Should Be Associated with More Prominent Effect of Liraglutide—Titrated from Insulin Degludec plus Liraglutide Combination Therapy

KOJI KASHIMA; HIROYUKI SHIMIZU; MASANOBU YAMADA

Jul 1, 2018Diabetes